[In vitro activity of β-lactamase inhibitors avibanvctam and relebactam in combination with β-lactams against multidrug-resistant Mycobacterium tuberculosis and mutations of resistance genes].

J Shi, D W Zheng, X G Ma, R Y Su, Y K Zhu, S H Wang, W J Chang, G Q Sun, D Y Sun
{"title":"[<i>In vitro</i> activity of β-lactamase inhibitors avibanvctam and relebactam in combination with β-lactams against multidrug-resistant <i>Mycobacterium tuberculosis</i> and mutations of resistance genes].","authors":"J Shi,&nbsp;D W Zheng,&nbsp;X G Ma,&nbsp;R Y Su,&nbsp;Y K Zhu,&nbsp;S H Wang,&nbsp;W J Chang,&nbsp;G Q Sun,&nbsp;D Y Sun","doi":"10.3760/cma.j.cn112147-20230111-00017","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the activity of six β-lactams in combination with three β-lactamase inhibitors against mycobacterium tuberculosis(MTB) <i>in vitro</i>. <b>Methods:</b> A total of 105 multidrug-resistant tuberculosis (MDR-TB) strains from different regions of Henan province from January to September 2020 were included in this study. Drug activity of six β-lactams (biapenem, meropenem, imipenem, doripenem, ertapenem and tebipenem) alone or in combination with β-lactamase inhibitors (clavulanic acid, avibactam and relebactam) was examined by minimum inhibitory concentration method (MICs) against 105 clinical isolates. Mutations of <i>blaC</i>, <i>ldt<sub>mt1</sub></i> and <i>ldt<sub>mt2</sub></i> were analyzed by PCR and DNA sequencing. Chi-square test was used to compare the antimicrobial activities of different β-lactam drugs. <b>Results:</b> Out of the β-lactams used herein, tebipenem was the most effective against MDR-TB and had an MIC<sub>50</sub> value of 8 mg/L(χ<sup>2</sup>=123.70,<i>P=</i>0.001). Besides, after the addition of β-lactamase inhibitors, the MICs of most β-lactam drugs were reduced more evidently in the presence of avibactam and relebactam compared to clavulanic acid.Especially, relebactam decreased both the MIC50 and MIC90 of telbipenem by 16-fold, and diluted the MIC of 23 (21.90%) and 41 (39.04%) isolatesby 32-fold and 16-fold.In addition, a total of 13.33% (14/105) of isolates harbored mutations in the <i>blaC</i> gene, with three different nucleotide substitutions: AGT333AGG, AAC638ACC and ATC786ATT. For the strains with Ser111Arg and Asn213Thr substitution in BlaC, the MIC values of the meropenem-clavulanate combination were reduced compared with a synonymous single nucleotide polymorphism (SNP) group. <b>Conclusions:</b> Both avibactam and relebactam had better synergistic effects on β-lactams than clavulanic acid. The combination of tebipenem and relebactam showed the most potent activity against MDR-TB isolates. In addition, the Ser111Arg and Asn213Thr substitution of BlaC may be associated with an increased susceptibility of MDR-TB isolates to meropenem in the presence of clavulanate.</p>","PeriodicalId":23961,"journal":{"name":"Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","volume":"46 8","pages":"797-805"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112147-20230111-00017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To evaluate the activity of six β-lactams in combination with three β-lactamase inhibitors against mycobacterium tuberculosis(MTB) in vitro. Methods: A total of 105 multidrug-resistant tuberculosis (MDR-TB) strains from different regions of Henan province from January to September 2020 were included in this study. Drug activity of six β-lactams (biapenem, meropenem, imipenem, doripenem, ertapenem and tebipenem) alone or in combination with β-lactamase inhibitors (clavulanic acid, avibactam and relebactam) was examined by minimum inhibitory concentration method (MICs) against 105 clinical isolates. Mutations of blaC, ldtmt1 and ldtmt2 were analyzed by PCR and DNA sequencing. Chi-square test was used to compare the antimicrobial activities of different β-lactam drugs. Results: Out of the β-lactams used herein, tebipenem was the most effective against MDR-TB and had an MIC50 value of 8 mg/L(χ2=123.70,P=0.001). Besides, after the addition of β-lactamase inhibitors, the MICs of most β-lactam drugs were reduced more evidently in the presence of avibactam and relebactam compared to clavulanic acid.Especially, relebactam decreased both the MIC50 and MIC90 of telbipenem by 16-fold, and diluted the MIC of 23 (21.90%) and 41 (39.04%) isolatesby 32-fold and 16-fold.In addition, a total of 13.33% (14/105) of isolates harbored mutations in the blaC gene, with three different nucleotide substitutions: AGT333AGG, AAC638ACC and ATC786ATT. For the strains with Ser111Arg and Asn213Thr substitution in BlaC, the MIC values of the meropenem-clavulanate combination were reduced compared with a synonymous single nucleotide polymorphism (SNP) group. Conclusions: Both avibactam and relebactam had better synergistic effects on β-lactams than clavulanic acid. The combination of tebipenem and relebactam showed the most potent activity against MDR-TB isolates. In addition, the Ser111Arg and Asn213Thr substitution of BlaC may be associated with an increased susceptibility of MDR-TB isolates to meropenem in the presence of clavulanate.

[β-内酰胺酶抑制剂阿维班克坦、乐巴坦联合β-内酰胺类药物对多药耐药结核分枝杆菌的体外活性及耐药基因突变研究]。
目的:评价6种β-内酰胺类药物联合3种β-内酰胺酶抑制剂体外抗结核分枝杆菌(MTB)的活性。方法:选取2020年1 - 9月来自河南省不同地区的105株耐多药结核病(MDR-TB)菌株作为研究对象。采用最小抑菌浓度法(mic)检测了6种β-内酰胺类药物(比阿培南、美罗培南、亚胺培南、多利培南、厄他培南和替比培南)单独或与β-内酰胺酶抑制剂(克拉维酸、阿维巴坦和乐巴坦)联合对105株临床分离菌株的药物活性。采用PCR和DNA测序方法对blaC、ldtmt1和ldtmt2基因突变进行分析。采用卡方检验比较不同β-内酰胺类药物的抑菌活性。结果:β-内酰胺类药物中,替比培南对耐多药结核病的抑制效果最好,其MIC50值为8 mg/L(χ2=123.70,P=0.001)。此外,加入β-内酰胺酶抑制剂后,与克拉维酸相比,大多数β-内酰胺类药物在阿维巴坦和瑞巴坦存在下的mic降低更为明显。其中,瑞巴坦使替比培南的MIC50和MIC90分别降低了16倍,将23株(21.90%)和41株(39.04%)的MIC50和MIC90分别稀释了32倍和16倍。此外,共有13.33%(14/105)的分离株存在blaC基因突变,并有3个不同的核苷酸替换:AGT333AGG、AAC638ACC和ATC786ATT。对于BlaC中Ser111Arg和Asn213Thr取代的菌株,与同义单核苷酸多态性(SNP)组相比,美罗培尼-克拉维酸组合的MIC值降低。结论:阿维巴坦和瑞巴坦对β-内酰胺的增效作用均优于克拉维酸。特比培南和瑞巴坦联合使用对耐多药结核分离株的活性最强。此外,BlaC的Ser111Arg和Asn213Thr取代可能与clavulanate存在时耐多药结核分离株对美罗培南的敏感性增加有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信